CareLit · DOI-Nachweis · Pneumologie
P53 disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI.
DOI 10.1055/s-0036-1572284
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Lüers, N Neemann, R Prenzel, DC Scriba, K Willborn, U Stropiep, M Falk, C Hallas, M Tiemann, F Griesinger
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: p53 mutations are common in lung cancer, and have also been described in EGFR mutated patients. The impact of p53 mutations in EGFR M+ patients is controversial, especially if classified as “disruptive” and “non-disruptive” according to their functional effect on the p53 protein as proposed by Poeta and colleagues. The aim of the study was therefore to systematically analyze EGFR and p53 mutations within…
Zitieren
Zitierempfehlung
A Lüers, N Neemann, R Prenzel, DC Scriba, K Willborn, U Stropiep, M Falk, C Hallas, M Tiemann, F Griesinger (2016) P53 disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI. Pneumologie (02). https://doi.org/10.1055/s-0036-1572284
Mit CareLit weiterarbeiten